ArticleScientific reports2026
Albumin levels and risk of early cardiovascular complications after endovascular thrombectomy for acute ischaemic stroke.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluate the clinical course of patients with hypoalbuminemia who underwent endovascular thrombectomy (EVT) within 24 h of acute ischaemic stroke (AIS). A retrospective cohort study using data from the global federated research network TriNetX. Adults ≥ 18 years treated with EVT for AIS between 2018 and 2024 with serum albumin measured within 24 h post-EVT were included. Patients were grouped by serum albumin levels: reduced (≤ 3.4 g/dL) vs. normal (≥ 3.5 g/dL). The primary outcome was a 30-day composite of all-cause death, acute heart failure, atrial fibrillation, ventricular arrhythmias, acute myocardial infarction, Takotsubo syndrome. Secondary outcomes included individual components and intracranial haemorrhage. Propensity score matching (1:1) balanced covariates, followed by Cox regression to estimate hazard ratios (HRs) and 95% confidence interval (CI)s. Among 8,698 patients with AIS treated with EVT, 6,233 had normal serum albumin (mean age 67.0 ± 14.5 years, 44.0% female), while 2,465 had reduced albumin (69.7 ± 14.3 years, 51.5% female). After matching, 2,374 patients with reduced albumin had higher risk of the composite outcome (HR 1.28, 95%CI 1.17-1.39), all-cause mortality (HR 1.72, 95%CI 1.50-1.96), and acute myocardial infarction (HR 1.74, 95%CI 1.28-2.35), compared to those with normal albumin. These associations remained consistent across subgroups stratified by age, sex, stroke severity, causes of hypoalbuminemia, degrees of hypoalbuminemia reduction. Hypoalbuminemia in patients with AIS treated with EVT is associated with an increased risk of early cardiovascular events. Serum albumin may be a prognostic biomarker in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.